Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years
Medidata has announced an extension of its 15-year relationship with the National Cancer Institute (NCI), part of the National Institutes of Health. This renewed commitment, spanning an additional five years, consolidates their joint efforts and underscores their dedication to advancing cancer research.
Since the inception of their partnership in 2008, Medidata and the NCI have collaborated across thousands of clinical trials with the joint mission of pioneering the development of promising treatments of cancer.
“Medidata’s long-standing partnership with the NCI represents our unwavering commitment to supporting critical oncology research,” says Joseph Schmidt, executive vice president, customer success, services, and support, Medidata in a press release. “It is gratifying that 90% of all oncology approvals last year in the US were developed using Medidata software, and we hope to make an even bigger impact alongside the NCI over the next few years in the fight against cancer.”
By standardizing processes and enhancing data collection, the Medidata platform supports accelerated study timelines with the goal of bringing innovative and transformative therapies to patients sooner.
The company’s combination of expertise and clinical trial technologies extends its support to public sector research organizations, encompassing over 3,000 academic clinical trials, 223,000 sites, and benefiting 948,000 patients.
Reference
Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years. (2023, October 4). Business Wire.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
